Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Nutrien Ltd (NTR) Price & Performance

Heron Therapeutics IncTrade
Nutrien LtdTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Nutrien Ltd — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while Nutrien Ltd trades at $66.75 (market cap $32.05B). The key difference: Nutrien Ltd is far larger — about 521.4× Heron Therapeutics Inc's market cap, and Nutrien Ltd pays a 3.27% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HRTXNTR
Market Cap
$61.47M$32.05B
Sector
HealthBasic Materials
52-Week High
$1.49$83.94
52-Week Low
$0.32$53.64
Enterprise Value
$168.21M$43.86B
Dividend Yield
3.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

Nutrien Ltd

Nutrien (NTR) trades at $66.31, up 2.93% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 earnings of $2.61 per share, missing estimates, though revenues benefited from higher potash prices. Fundamentals show solid profitability with 8.44% net margin and reasonable valuation at P/E of 13.62. Recent dividend declarations of $0.55 per share demonstrate shareholder returns commitment.

NTR presents value opportunity with analyst consensus target of $76.17 (15% upside) and strong buy ratings (61%). However, earnings volatility, declining cash flow trends, and agricultural cycle sensitivity pose risks. The stock's appeal hinges on execution amid input cost pressures and global fertilizer demand recovery.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Nutrien Ltd

Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.

Read more on NTR